Published in Gene Therapy Weekly, June 15th, 2000
According to J. Goater and colleagues, University of Rochester, New York, "A recombinant AAV (rAAV) vector expressing the bacterial beta-galactosidase (beta-gal) gene (rAAV-CMV-LacZ) was directly introduced into healthy-normal mouse knees, or arthritic knees in mice overexpressing tumor necrosis factor-alpha (hTNF alpha-Tg)" ("Empirical advantages of adenoassociated viral vectors for in vivo gene therapy for arthritis," Journal of Rheumatology, 2000;27(4):983-989).
The researchers used immunohistochemistry and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.